Merrimack Pharmaceuticals Inc

-0.17 (-1.41%)
Products, Regulatory

Merrimack Provides Ipsen Report That Onivyde Regimen Demonstrated Improvement In Survival In Metastatic Pancreatic Ductal Adenocarcinoma

Published: 11/09/2022 16:11 GMT
Merrimack Pharmaceuticals Inc (MACK) - Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
Merrimack Pharmaceuticals Inc- Trial Met Its Primary Endpoint.
Merrimack Pharmaceuticals Inc- Safety Profile of Onivyde in Napoli 3 Trial Was Consistent With Those Observed in Previous Phase I/ii Mpdac Study.
Merrimack Pharmaceuticals Inc- Intends to File a Supplemental New Drug Application With U.S. Food and Drug Administration for Onivyde.